These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

453 related articles for article (PubMed ID: 32194568)

  • 21. Immune Checkpoint Inhibitor-induced Reinvigoration of Tumor-infiltrating CD8
    Park J; Kwon M; Kim KH; Kim TS; Hong SH; Kim CG; Kang SG; Moon JH; Kim EH; Park SH; Chang JH; Shin EC
    Clin Cancer Res; 2019 Apr; 25(8):2549-2559. PubMed ID: 30659023
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic and therapeutic role of tumor-infiltrating lymphocyte subtypes in breast cancer.
    Nelson MA; Ngamcherdtrakul W; Luoh SW; Yantasee W
    Cancer Metastasis Rev; 2021 Jun; 40(2):519-536. PubMed ID: 33963482
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumour-infiltrating lymphocytes and expression of programmed death ligand 1 (PD-L1) in melanoma brain metastases.
    Berghoff AS; Ricken G; Widhalm G; Rajky O; Dieckmann K; Birner P; Bartsch R; Höller C; Preusser M
    Histopathology; 2015 Jan; 66(2):289-99. PubMed ID: 25314639
    [TBL] [Abstract][Full Text] [Related]  

  • 24. CD103
    Edwards J; Wilmott JS; Madore J; Gide TN; Quek C; Tasker A; Ferguson A; Chen J; Hewavisenti R; Hersey P; Gebhardt T; Weninger W; Britton WJ; Saw RPM; Thompson JF; Menzies AM; Long GV; Scolyer RA; Palendira U
    Clin Cancer Res; 2018 Jul; 24(13):3036-3045. PubMed ID: 29599411
    [No Abstract]   [Full Text] [Related]  

  • 25. Tumor infiltrating lymphocyte clusters are associated with response to immune checkpoint inhibition in BRAF V600
    Klein S; Mauch C; Brinker K; Noh KW; Knez S; Büttner R; Quaas A; Helbig D
    Sci Rep; 2021 Jan; 11(1):1834. PubMed ID: 33469107
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Distinct Immune Cell Populations Define Response to Anti-PD-1 Monotherapy and Anti-PD-1/Anti-CTLA-4 Combined Therapy.
    Gide TN; Quek C; Menzies AM; Tasker AT; Shang P; Holst J; Madore J; Lim SY; Velickovic R; Wongchenko M; Yan Y; Lo S; Carlino MS; Guminski A; Saw RPM; Pang A; McGuire HM; Palendira U; Thompson JF; Rizos H; Silva IPD; Batten M; Scolyer RA; Long GV; Wilmott JS
    Cancer Cell; 2019 Feb; 35(2):238-255.e6. PubMed ID: 30753825
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Baseline β-catenin, programmed death-ligand 1 expression and tumour-infiltrating lymphocytes predict response and poor prognosis in BRAF inhibitor-treated melanoma patients.
    Massi D; Romano E; Rulli E; Merelli B; Nassini R; De Logu F; Bieche I; Baroni G; Cattaneo L; Xue G; Mandalà M
    Eur J Cancer; 2017 Jun; 78():70-81. PubMed ID: 28412591
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Predominance of Central Memory T Cells with High T-Cell Receptor Repertoire Diversity is Associated with Response to PD-1/PD-L1 Inhibition in Merkel Cell Carcinoma.
    Spassova I; Ugurel S; Terheyden P; Sucker A; Hassel JC; Ritter C; Kubat L; Habermann D; Farahpour F; Saeedghalati M; Peiffer L; Kumar R; Schrama D; Hoffmann D; Schadendorf D; Becker JC
    Clin Cancer Res; 2020 May; 26(9):2257-2267. PubMed ID: 31932494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A20 regulates the therapeutic effect of anti-PD-1 immunotherapy in melanoma.
    Guo W; Ma J; Guo S; Wang H; Wang S; Shi Q; Liu L; Zhao T; Yang F; Chen S; Chen J; Zhao J; Yu C; Yi X; Yang Y; Ma J; Ni Q; Zhu G; Gao T; Li C
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298620
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumor fitness, immune exhaustion and clinical outcomes: impact of immune checkpoint inhibitors.
    Bubie A; Gonzalez-Kozlova E; Akers N; Villanueva A; Losic B
    Sci Rep; 2020 Mar; 10(1):5062. PubMed ID: 32193450
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Regulation of PD-1 in T cells for cancer immunotherapy.
    Yu X; Gao R; Li Y; Zeng C
    Eur J Pharmacol; 2020 Aug; 881():173240. PubMed ID: 32497624
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Close proximity of immune and tumor cells underlies response to anti-PD-1 based therapies in metastatic melanoma patients.
    Gide TN; Silva IP; Quek C; Ahmed T; Menzies AM; Carlino MS; Saw RPM; Thompson JF; Batten M; Long GV; Scolyer RA; Wilmott JS
    Oncoimmunology; 2020; 9(1):1659093. PubMed ID: 32002281
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Checkpoint Blockade Immunotherapy Induces Dynamic Changes in PD-1
    Kurtulus S; Madi A; Escobar G; Klapholz M; Nyman J; Christian E; Pawlak M; Dionne D; Xia J; Rozenblatt-Rosen O; Kuchroo VK; Regev A; Anderson AC
    Immunity; 2019 Jan; 50(1):181-194.e6. PubMed ID: 30635236
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clonality of CD4
    Arakawa A; Vollmer S; Tietze J; Galinski A; Heppt MV; Bürdek M; Berking C; Prinz JC
    Front Immunol; 2019; 10():1336. PubMed ID: 31275310
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Immune checkpoint protein and cytokine expression by T lymphocytes in pleural effusion of cancer patients receiving anti-PD-1 therapy.
    Ikematsu Y; Tanaka K; Yanagihara T; Liu R; Inoue H; Yoneshima Y; Ota K; Iwama E; Takata S; Hata K; Takahata Y; Wataya H; Nakanishi Y; Okamoto I
    Lung Cancer; 2019 Dec; 138():58-64. PubMed ID: 31639551
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Generation, Transcriptomic States, and Clinical Relevance of CX3CR1+ CD8 T Cells in Melanoma.
    Ishigaki H; Yamauchi T; Long MD; Hoki T; Yamamoto Y; Oba T; Ito F
    Cancer Res Commun; 2024 Jul; 4(7):1802-1814. PubMed ID: 38881188
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stromal PD-L1-Positive Regulatory T cells and PD-1-Positive CD8-Positive T cells Define the Response of Different Subsets of Non-Small Cell Lung Cancer to PD-1/PD-L1 Blockade Immunotherapy.
    Wu SP; Liao RQ; Tu HY; Wang WJ; Dong ZY; Huang SM; Guo WB; Gou LY; Sun HW; Zhang Q; Xie Z; Yan LX; Su J; Yang JJ; Zhong WZ; Zhang XC; Wu YL
    J Thorac Oncol; 2018 Apr; 13(4):521-532. PubMed ID: 29269008
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination anti-CTLA-4 plus anti-PD-1 checkpoint blockade utilizes cellular mechanisms partially distinct from monotherapies.
    Wei SC; Anang NAS; Sharma R; Andrews MC; Reuben A; Levine JH; Cogdill AP; Mancuso JJ; Wargo JA; Pe'er D; Allison JP
    Proc Natl Acad Sci U S A; 2019 Nov; 116(45):22699-22709. PubMed ID: 31636208
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PD-1
    Donia M; Kjeldsen JW; Andersen R; Westergaard MCW; Bianchi V; Legut M; Attaf M; Szomolay B; Ott S; Dolton G; Lyngaa R; Hadrup SR; Sewell AK; Svane IM
    Clin Cancer Res; 2017 Oct; 23(19):5779-5788. PubMed ID: 28679768
    [No Abstract]   [Full Text] [Related]  

  • 40. Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
    Chen PL; Roh W; Reuben A; Cooper ZA; Spencer CN; Prieto PA; Miller JP; Bassett RL; Gopalakrishnan V; Wani K; De Macedo MP; Austin-Breneman JL; Jiang H; Chang Q; Reddy SM; Chen WS; Tetzlaff MT; Broaddus RJ; Davies MA; Gershenwald JE; Haydu L; Lazar AJ; Patel SP; Hwu P; Hwu WJ; Diab A; Glitza IC; Woodman SE; Vence LM; Wistuba II; Amaria RN; Kwong LN; Prieto V; Davis RE; Ma W; Overwijk WW; Sharpe AH; Hu J; Futreal PA; Blando J; Sharma P; Allison JP; Chin L; Wargo JA
    Cancer Discov; 2016 Aug; 6(8):827-37. PubMed ID: 27301722
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.